Despite advances in prevention, screening, and treatment, colorectal cancer (CRC) remains the 3rd most commonly diagnosed cancer and the 2nd leading cause of cancer deaths among men and women combined in the US. Nearly 1.2 million CRC survivors currently living in the US are at risk of adverse CRC outcomes. The large number of CRC survivors coupled with the considerable financial burden of CRC makes it critical to identify biomarkers to predict recurrence among CRC patients that can be used to guide clinical decisions regarding treatment and surveillance. Currently there are no definitive biomarkers to identify colon cancer with a high likelihood to recur. The human gut contains the largest bacterial ecosystem (gut microbiome) in the human body. However, whether the gut microbiome (directly or indirectly via bacterial metabolites) is associated with CRC recurrence is unknown. Lastly, given the prevalence, and often overuse, of antibiotics and proton pump inhibitors (PPIs) in the population, and their effects on the gut microbiome, the association of antibiotic and PPI use with CRC recurrence needs to be investigated. To address these knowledge gaps, the proposed study seeks to generate high-throughput 16S sequencing data to investigate the associations of tumor-specific gut microbial profiles with colon cancer recurrence. This study will be conducted in two phases. In the discovery phase, we will identify bacterial profiles associated with early recurrence in 283 colon cancer stage II/III patients with available snap frozen tumor tissue. In the validation phase, top bacterial candidates from our discovery phase will be evaluated in an independent set of 600 stage II/III colon cancer patients. Finally, taking advantage of a wealth of high-quality data in Danish medical, clinical, and population registries, we will examine whether pre-diagnostic antibiotic therapy and proton pump inhibitor (PPI) use are associated with recurrence among >21,000 CRC patients diagnosed between 2001 and 2012 in Denmark. The findings of our study will contribute to identification of potential tumor-specific biomarkers of colon cancer recurrence, and clarify the possible roles of the gut microbiome in colon cancer progression.
Colorectal cancer remains the second leading cause of cancer deaths in the US. The purpose of this study is to identify and verify biomarkers of recurrence risk among patients diagnosed with colon cancer, and assess whether exposure to antibiotics and proton pump inhibitor (PPI) use are associated with colorectal cancer progression. We expect this project to help identify colon cancer patients at highest risk for recurrence, clarify the possible roles of the bacteria of the human colon (gut microbiome) in colon cancer progression, and design effective tertiary prevention strategies against colorectal cancer recurrence.
|Hodge, Rebecca; Mandle, Hannah B; Ray, Stephen et al. (2018) Effects of Supplemental Calcium and Vitamin D on Expression of Toll-Like Receptors and Phospho-IKK?/? in the Normal Rectal Mucosa of Colorectal Adenoma Patients. Cancer Prev Res (Phila) 11:707-716|